S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Key Points

  • Johnson & Johnson shares formed a cup-shaped pattern that appeared to add a handle, and came within 12 cents of passing an interim high price of $181.04 before breaking down on January 9. 
  • News broke recently of a dissolved partnership with Fate Therapeutics for cancer treatments.
  • The company is also slashing production of its unpopular Covid-19 vaccine. 
  • It's due to report Q4 results next week, with Wall Street expecting year-over-year growth on the bottom line. 
  • 5 stocks we like better than Johnson & Johnson

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

As a member of the 30-stock Dow Jones Industrial Index and a heavily-weighted component of the S&P 500, Johnson & Johnson (NYSE: JNJ) is a stock that naturally gets a lot of attention from investors.

The stock has been struggling to break out of a correction that began in April last year. It formed a cup-shaped pattern that appeared to add a handle and came within 12 cents of passing an interim high price of $181.04 before breaking down on January 9. 

Shares sliced through their 50-day average on January 9, and ended Tuesday’s session 0.6% below their 200-day line.

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

While that’s not good news in the near term, it’s unlikely that investors would stampede for the exits in an institutional quality stock like Johnson & Johnson, which has a market capitalization of $450.63 billion. It’s the ninth largest component of the S&P 500 and the second largest, behind UnitedHealth Group Incorporated (NYSE: UNH) in the S&P healthcare sector. 

Johnson & Johnson shares are down 3.78% in the past week. The company confirmed some news that had been previously signaled: It’s reducing the production of its Covid-19 vaccines, which failed to gain the popularity of those created by rivals Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA).  


Earlier in the month, pharmaceutical contract manufacturer Emergent BioSolutions Inc. (NYSE: EBS) said it would be restructuring and laying off employees to improve business performance. Emergent had been a manufacturer of J&J’s Covid vaccines but had a highly publicized mistake in 2020 when ingredients from J&J’s vaccine were mixed with those of AstraZeneca PLC (NASDAQ: AZN)

The AstraZeneca vaccine was immediately manufactured elsewhere, and the U.S. government eventually terminated its contract with Emergent. 

Emergent Says It’s Owed $420 Million

Emergent now says J&J owes it as much as $420 million for breach of contract. 

There was another fairly significant piece of company-specific news for Johnson & Johnson last week. Fate Therapeutics Inc (NASDAQ: FATE) terminated an agreement with J&J business unit Janssen Biotech originally touted as having the potential for $3 billion in revenue. The agreement, forged in 2020, was established to jointly develop cancer therapies. 

In the announcement terminating the agreement, Fate CEO Scott Wolchko said, “We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration." 

San Diego-based Fate Therapeutics develops immunotherapies for the treatment of cancers. Its shares dropped more than 61% on the news.

J&J shares broke down 2.5% on January 9, the day CEO Joaquin Duato spoke at the J.P. Morgan Healthcare Conference, saying the company is seeking merger and acquisition opportunities in the areas of orthopedic and cardiovascular, surgical robotics, and eye care. 

The company last month completed its acquisition of cardiac device maker Abiomed for $16.6 billion. 

Consumer Products Unit Spinoff

Johnson & Johnson is spinning off its consumer healthcare unit (think Band-Aid, Neutrogena, Listerine, and Tylenol, among other products). The new business will be dubbed Kenvue and trade on the Nasdaq under the ticker KVUE. 

Kenvue has filed regulatory paperwork for an IPO, but there’s no date yet for the pricing. 

J&J said it expects the spinoff to be completed by November this year. Current J&J shareholders will still own their shares but receive Kenvue shares. 

At the time of the spinoff announcement, J&J said, “It is expected that the overall shareholder dividend will remain at least at the same level following the completion of the transaction.”

Dividends are a key reason investors are drawn to well-established large caps like J&J. The company has a long history of dividend payments and increases, making it an attractive holding even during market downturns when a dividend payment can offset some price declines. 

J&J’s current yield is 2.62%, as MarketBeat data show.

The company is due to report fourth-quarter results on January 24 before the opening, with Wall Street expecting a net income of $2.22 a share on revenue of $23.91 billion. 

That would be a decrease in the top line and an increase on the bottom line. 

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2022

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
The Best High-Yield Dividend Stocks for 2022 Cover

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
2.8975 of 5 stars
$168.23-0.4%2.69%24.96Hold$182.75
UnitedHealth Group (UNH)
3.4027 of 5 stars
$486.05-1.3%1.36%22.94Moderate Buy$599.39
Pfizer (PFE)
3.0797 of 5 stars
$43.79-1.0%3.75%8.42Hold$52.33
Moderna (MRNA)
2.184 of 5 stars
$189.35-2.0%N/A6.85Hold$192.00
Emergent BioSolutions (EBS)
2.6283 of 5 stars
$13.47+2.7%N/A17.27Hold$36.75
AstraZeneca (AZN)
2.3871 of 5 stars
$65.53-0.7%1.39%97.81Hold$98.00
Fate Therapeutics (FATE)
2.8039 of 5 stars
$5.92+11.7%N/A-1.94Hold$29.75
Compare These Stocks  Add These Stocks to My Watchlist 

Kate Stalter

About Kate Stalter

Contributing Author: Retirement, Asset Allocation, and Tax Strategies

Kate Stalter is a Series 65-licensed asset manager, with more than two decades of experience in various areas of financial services. As an investment advisor and financial planner, Kate personally manages client portfolios, with a focus on successful retirement, including asset allocation, income generation and tax strategies. Kate also serves as a capital-markets contributor at Forbes.com, and is an expert columnist for the investment advisory channel at U.S. News & World Report.
Contact Kate Stalter via email at stalterkate@gmail.com.

Featured Articles and Offers

Search Headlines: